Search Results for: Q BioMed Announces Development Partnership
Articles
Q BioMed Announces Development Partnership With Sphaera Pharma September 25, 2017
Q BioMed Inc. recently announced a partnership with Sphaera Pharma to develop a new and proprietary analog of QBM-001 for...Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases With University of Florida January 30, 2024
Vaxxinity, Inc. recently announced a research collaboration with the University of Florida’s (UF) Center for Translational Research in Neurodegenerative Disease (CTRND)...GRI Bio Announces Partnership With the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression October 17, 2023
GRI Bio, Inc. recently announced it has entered into a collaboration with the UK consortia, National Institute for Health and...Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development August 22, 2023
Revive Therapeutics Ltd. recently announced it has initiated the development of a next-generation formulation of Bucillamine for the potential treatment...Paratek Pharmaceuticals Announces Positive Top Line Data From Pilot Efficacy Study for the Treatment of Pulmonary Anthrax & Acceptance of the Second Procurement of NUZYRA Under BARDA Project BioShield December 19, 2022
Paratek Pharmaceuticals, Inc. recently announced positive top line data from a pilot rabbit efficacy study evaluating NUZYRA’s effectiveness in the treatment of pulmonary anthrax. In the study, a 100% survival rate….
Heat Biologics Announces Planned Acquisition of Elusys Therapeutics December 21, 2021
Heat Biologics, Inc. recently announced it has executed a definitive merger agreement to acquire Elusys Therapeutics, a commercial-stage biodefense company and the manufacturer of ANTHIM (obiltoxaximab) Injection,….
Adynxx Announces Merger Agreement With Alliqua BioMedical April 25, 2019
Adynxx, Inc. recently provided a business and clinical development update. Adynxx entered into a merger agreement with Alliqua Biomedical, Inc....ContraFect Announces $6.94 Million in Funding from CARB-X March 7, 2019
ContraFect Corporation recently announced that the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has awarded the company up to $6.94...Bavarian Nordic Announces Exercise of $44-Million Option by BARDA January 18, 2019
Bavarian Nordic A/S recently announced the US Biomedical Advanced Research and Development Authority (BARDA) have exercised another option under the ongoing contract for freeze-dried MVA-BN smallpox vaccine.
Axovant Licenses Investigational Gene Therapy for Parkinson’s Disease From Oxford BioMedica; Announces Key Leadership Team Addition June 6, 2018
Axovant Sciences recently announced that it has licensed the exclusive worldwide rights to develop and commercialize OXB-102, now AXO-Lenti-PD, from Oxford BioMedica. AXO-Lenti-PD is an investigational gene therapy for Parkinson’s disease that delivers three genes encoding a critical set of enzymes required for dopamine synthesis in the brain.
Envigo Announces Successful AAALAC Accreditation June 6, 2017
Envigo has announced that its Research Models and Services (RMS) facility in Hyderabad, India, has been granted full accreditation by...ADVANCED DELIVERY DEVICES - Implantable Drug-Eluting Devices: A Novel Approach to Patient Care October 6, 2015
Samuel D. Trohman, MBA, Joey L. Glassco, Elena Draganoiu, PhD, and Carey Boyum present developmental and commercial examples of non-biodegradable drug-eluting devices, along with the versatile properties of thermoplastic polyurethanes for the development of effective drug delivery systems.
1/30/2013 January 27, 2013
Baxter International Makes $700-Million Acquisition Inspiration Biopharmaceuticals and Ipsen recently announced the sale of its lead hemophilia program, OBI-1 (recombinant...10/30/2012 October 25, 2012
Arthritis Signifies a Vast Untouched Market, Finds Frost & Sullivan Tumor necrosis factor (TNF) inhibitors are currently the only therapeutic...10/3/2012 October 1, 2012
Actinium Announces Multi-Million Financing Actinium Pharmaceuticals, Inc. recently announced it has engaged Laidlaw & Company (UK) Ltd. and launched a...4/12/2011 April 7, 2011
IBM & the Institute of Bioengineering & Nanotechnology Find Breakthrough TreatmentResearchers from IBM and the Institute of Bioengineering and Nanotechnology...3/15/2011 March 13, 2011
Cytheris Announces Study Results Indicating CYT107 Expands CD4 T-Cells Cytheris SA, a clinical-stage biopharmaceutical company focused on research and development...
